Percutaneous Aortic Valve Interventions (Michael J. Reardon, MD)
Michael J. Reardon, MD: The TAVR Study for Low-Risk Mortality
TMVR - Hope or Hype (Michael J. Reardon, MD)
AVR, Valve Types, TAVI (Michael J. Reardon, MD) Sunday, August 21, 2016
Michael J. Reardon, MD: Long-Term TAVR Plans
Complex Cases 1: Good, Bad, Ugly (Michael J. Reardon, MD) May 1, 2016
Low Risk TAVR: What the Data Tells Us (Michael J. Reardon, MD) March 26, 2020
TAVR-Device Selection & Expanding Indications/Percutaneous Alt. Access (Michael J. Reardon, MD)
TAVR (Michael J. Reardon, MD) - April 6th, 2017 Re-Evolution Summit
Re-Evolution Summit Interview (Michael Deeb, MD/ Michael J. Reardon, MD)
Complex Cases 3 & 4: Good, Bad, Ugly (Michael J. Reardon, MD)
Bicuspid Valve Aortopathy: Surgical and Medical Considerations (Michael J. Reardon, MD)
Transcatheter Heart Valves Greece 2024, Michael J. Reardon, Gregory Pattakos
Michael Reardon: How Will Transcatheter Therapies Shape the Future?
TAVR Data for the Surgeon (Michael Reardon, MD)
Michael J Reardon, MD on durability of TAVR in patients with aortic stenosis with Chadi Alraies, MD
Michael J Reardon, MD - TAVR in Asymptomatic or Moderate AS
Continuing a Cardiac Tumor Program Legacy - Houston Methodist (Michael J. Reardon, MD)
TAVR Horizons: Partner II, SurTAVI and Beyond (Michael J. Reardon, MD) April 30, 2016
Faculty Interview with Dr. Michael Reardon | CardioVascular Interventions Summit 2024